| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1371499 | Bioorganic & Medicinal Chemistry Letters | 2012 | 6 Pages |
Abstract
This Paper describes the continued optimization of an MLPCN probe molecule M1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Bruce J. Melancon, Thomas J. Utley, Christian Sevel, Margrith E. Mattmann, Yiu-Yin Cheung, Thomas M. Bridges, Ryan D. Morrison, Douglas J. Sheffler, Colleen M. Niswender, J. Scott Daniels, P. Jeffrey Conn, Craig W. Lindsley, Michael R. Wood,